Confusion abounds on how to treat the menopause

Key points
- The results in 2002 of a large U.S. study on hormone replacement therapy (HRT) in many respects left women confused and alarmed about the treatment for the menopause.
- At that time the Women's Health Initiative (WHI) study indicated that women taking Prempro, a popular combination of synthetic estrogen and progesterone, increased their risk of heart attacks and breast cancer, while decreasing the chance of colon cancer and bone fractures.
- It advised that postmenopausal women should not take hormones for disease prevention, as opposed to relief from menopausal symptoms, because the risks outweighed the benefits.
- However the same was not true for women who had undergone a hysterectomy as they were found to have significantly increased rates of stroke and blood clots, but a lower risk of breast cancer and hip fracture.
The results in 2002 of a large U.S. study on hormone replacement therapy (HRT) in many respects left women confused and alarmed about the treatment for the menopause.
At that time the Women's Health Initiative (WHI) study indicated that women taking Prempro, a popular combination of synthetic estrogen and progesterone, increased their risk of heart attacks and breast cancer, while decreasing the chance of colon cancer and bone fractures.
It advised that postmenopausal women should not take hormones for disease prevention, as opposed to relief from menopausal symptoms, because the risks outweighed the benefits.
However the same was not true for women who had undergone a hysterectomy as they were found to have significantly increased rates of stroke and blood clots, but a lower risk of breast cancer and hip fracture.
Overall the lingering impression was that HRT was essentially not a good thing, even though the total number of hormone-therapy users affected by the risks or benefits were small.
The average age for menopause in the U.S. is 51, but for the vast majority of women it occurs between 44 and 56.
Around 1 percent of women experience a 'perimenopause' before age 40 when menstrual periods start to become irregular and ends one year after they stop altogether.
Perimenopause, which for the average woman starts at age 46, usually lasts from two to eight years.
For the average woman, fertility begins to decline around age 37, but women who don't want to get pregnant should continue to use contraception until they are definitely postmenopausal.
Scientists now know that it is the fluctuation in hormone levels which cause the hot flashes of the menopause which are more common in early postmenopause than in perimenopause, which eventually peter out.
Acne and thinning hair sometimes reflect hormonal changes, but can stop after hormone levels settle down.
However osteoporosis and vaginal thinning are more likely to get worse with age, unless women take estrogen.
Since 2002 hormone replacement therapy and its use has significantly changed and numerous remedies have hit the market, offering a range of treatments to treat the symptoms of menopause, which has left many women in a state of confusion and vulnerable to what is often unqualified advice.
Many of the so-called 'non-drug' or 'natural' alternatives are themselves harmful and lack any regulated track history.
The popular "bio-identical hormones" currently being advocated on the internet and by some celebrities as being 'natural' with the ability to replicate the body's naturally produced estrogen, are in reality chemically produced hormones.
A bio-identical hormone is a custom-made recipe containing hormones in differing amounts and are often produced as creams, gels, liquids or sprays which often contain several other ingredients.
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Women's Health →
NewsCelmatix study shows women may be stopping IVF treatment prematurely
Celmatix, a biotechnology company focused on helping physicians guide patients to treatments that maximize their personal reproductive potential, announced today six research presentations at the annual meeting of the…
18 October 2013
NewsBritish women 50 percent less likley to receive treatment for common menopausal symptoms
New data, published today in Menopause International, suggests that post-menopausal women in Britain are experiencing less sex, and less satisfying sex compared to their European and North American counterparts, because…
20 June 2013
NewsNew research findings on onset of uterine fibroids provide potential for novel treatments
Uterine leiomyomata, or fibroids, are benign tumours that nevertheless affect the health of millions of women. They may cause, for instance, pain, bleeding and infertility. Fibroids are also the most common reason for a…




